Since 1910, Abbott has been dedicated to helping people in India live healthier lives through a diverse range of science-based nutritional products, diagnostic tools, branded generic pharmaceuticals, and diabetes and vascular devices. Abbott India Limited is a public limited company domiciled and incorporated in India under the provisions of the then Companies Act, 1913. The company is listed and traded on the Bombay Stock Exchange. It is traded on the National Stock Exchange under the ‘permitted category’.
Abbott India, a publicly listed company and a subsidiary of Abbott Laboratories, takes pride in offering high-quality trusted medicines in multiple therapeutic categories such as women's health, gastroenterology, cardiology, metabolic disorders and primary care.
One of India's fastest-growing pharmaceutical companies, Abbott India Limited is part of Abbott's global pharmaceutical business in India. It has expertise across product development, manufacturing, sales and customer service and dedicated to providing high-quality, reliable products with the expert clinical support customers need.
Abbott India provides quality healthcare through a mix of global and local products for people in India. Its in-house development and medical teams undertake product and clinical development tailored to the unique needs of the Indian market. Its employees work to produce high-quality, high-volume formulations using cost efficient processes. And, its trained personnel are dedicated to ensuring compliance with international quality standards.
The company is one of the leading multinational pharmaceutical companies in India and operates with owned manufacturing units and various independent contract/third party manufacturers based across the country. The company sells its products through independent distributors primarily within India.
2013- Awarded Frost & Sullivan ‘MNC Pharmaceutical Company of the Year’ for the third consecutive year.
2014 -Abbott, one of the largest diversified global healthcare companies and the number one pharmaceutical company in India, in partnership with the Indian Thyroid Society (ITS), announced the launch of a thyroid awareness initiative in Uttar Pradesh and Uttarakhand.
2014- Abbott was awarded the prestigious Golden Peacock Innovation Management Award at the 8th International Conference on Corporate Social Responsibility held in Bangalore.
2018- ‘Best Companies to Work’
2018- Best Use Of Technology for Training Excellence in The Production of Learning Content
2019- Company of the Year (Abbott India)
2019- Brand of the Year (Thyronorm) by AWACS
2019- Excellence in Content Development for e-detailing training - Rajni ka iPad by National Awards for Training and Development
2019- Gold for Best Content in a B-2-B Marketing Campaign - Immersive storytelling (using AR) for doctors at the India Content Leadership Award
2019- Outstanding patient support for Gutfit by CMO Asia
2019- Gold Award for Best Use of Market Research - PR MomvsFlu by Global Customer Engagement.
2020- Best Financial Content For The 75th Annual Report at India Content Leadership Awards
2020- Cremaffin Plus - Brand Excellence Award in Pharmaceutical sector at ABP Brand Excellence Award.
2020- GUTFIT - Best Patient Education Project Award at ZEE Business’s - National Healthcare Leadership Awards
2020- UDILIV - Brand Of The Year -Bronz at the AWACS Award - Acute category
2020- Best Patient-Centric Design At Pharmapack Europe - G’DoCon - Granule Dosing Concept of CREON SD
2020- Best Digital Media Content by a Healthcare Enterprise for Mother Against Influenza (MAI) at the India Content Leadership Awards
Dr. Abbott’s spirit of entrepreneurship, innovation and caring lives on in culture, business and contributions to medical science. Read below for historical moments that highlights the pursuit of the extraordinary throughout the years.
1888- Production of ‘alkaloidal’ medicine granules by Dr. Wallace C. Abbott, a 30-year-old practicing physician, begins in the rear of his People’s Drug Store in Chicago. Remedies contain the active ingredients of plants and herbs. First-year total sales reach $2,000.
1894- Incorporated as the Abbott Alkaloidal Company. Abbott is a medical publisher as well as a manufacturer.
1907- Expansion outside the United States for the first time with an office in London, England.
1916- Production of first synthetic medicine, Chlorazene, a breakthrough antiseptic developed by British chemist Dr. Henry Dakin to treat wounded soldiers in World War I.
1922- Development of Butyn by scientists Dr. Ernest Volwiler and Dr. Roger Adams, the first in a long line of breakthrough anesthetics to come from company.
1929- Initial public offering provides shares for the first time in the year of the stock market crash that began the Great Depression. While the timing seems inauspicious, stock grows in value from that first day-and approximately 10,000 times over so far.
1932- Expansion continues even at the height of the Great Depression thanks to leadership in new fields such as vitamins and intravenous solutions. “Few of the leading industrial organizations of the country,” notes Nation’s Commercemagazine, “can show a sounder record for the past year than the Abbott Laboratories.”
1935- Introduction of Pentothal, which will be the world’s leading anesthetic for years to come and win inventors, Dr. Volwiler and Dr. Donalee Tabern, induction into the U.S. National Inventors Hall of Fame.
1942- Abbott joins a consortium of pharmaceutical makers, at the behest of the U.S. Government, to ramp up production of penicillin for wartime use. Together it increase production more than 20,000%.
1959- Adoption of Abbott “A” logo, a classic of industrial design that remains the cornerstone of visual identity to this day.
1960- Reinvention in the 1960s under
featured in the 2001
best-seller, Good to
Great- Why Some
Companies Make the
Leap... and Others Don’t. Author Jim Collins
chose as one of 11 companies, out of 1,435, that had the product, service, organizational and people quality to engender truly great performance.
1964- Acquisition of M&R Dietetics, with its popular baby formula, Similac, makes a leader in nutrition.
1972- Introduction of the ABA-100 blood chemistry analyzer as well as Ausria, a breakthrough radioimmunoassay test for detecting serum hepatitis. This marks the beginning of modern diagnostics business, in which it quickly became a world leader.
1985- Approval of the first licensed test to identify the HIV virus in blood, helping to secure the safety of the blood supply. This is one of greatest achievements and the first significant medical victory against what had, until then, seemed an unstoppable threat.
1998- Introduction of Glucerna, a group of cereals, health shakes and snack bars formulated specifically for diabetics and others with dietary restrictions.
2002- FDA approval of Humira, the first fully-human monoclonal antibody drug. It will go on to become the world's leading pharmaceutical product.
2006- Launch of the Xience V drug-eluting stent. It goes on to become the market leader.
2010- Continue its focus on globalism as it becomes the largest pharmaceutical company in India, the world’s second-largest country by population.
2013- Beginning of a new era for Abbott, as a more global, consumer-focused company than ever before, it created a new, Fortune 200 corporation, AbbVie, from former proprietary pharmaceutical business.
2014- Abbott establishes a strong new expression of its corporate identity with “Life. To The Fullest.” The company promotes its identity more vigorously than ever before, advertising to consumer audiences around the world and becoming the sponsor of the Abbott World Marathon Majors, a series of the world’s most prominent races.
2014- With the launch of its cutting-edge continuous glucose monitoring system, FreeStyle Libre, Abbott revolutionizes diabetes care by eliminating the need for routine fingersticks.1
2016- Abbott launches the first systems in its Alinity series, a family of diagnostics and informatics systems that represent a major leap forward in terms of reliability, cost, capacity, space efficiency, and ease of use. It are creating the future of diagnostic labs.
2017- In its largest acquisition ever, Abbott acquires St. Jude Medical, adding breakthrough inventions and extensive expertise across the areas of cardiovascular and neuromodulation. Abbott now competes in nearly every area of cardiovascular health and holds the No. 1 or 2 positions in a variety of large, high-growth markets.
2017- Abbott acquires Alere Inc., making Abbott the leader in point-of-care diagnostic technology filling out its array of diagnostics technologies. Abbott now holds the No. 1 position in rapid testing for cardiometabolic disease, infectious disease and in toxicology.
2018- For women health, company has launched Estrabet Gel, Doxstem, Combinorm Wash, Fertifoid
2019- To help improve diagnosis and treatment of thyroid disorders, bacterial vaginosis and Vitamin D, the company collaborated with Indian Thyroid Society (ITS) and Federation of Obstetric and Gynecological Societies of India (FOGSI) to initiate the Metabolic Women’s Health workshops.
2020- Abbott has launched a new inactivated quadrivalent vaccine for influenza offering protection against four virus strains in India. It is the only 0.5 ml quadrivalent flu vaccine in India that has been approved for use in children below three years.
2020- Abbott has received approval from the Drugs Controller General of India (DCGI) for its once-a-day formulation, Ivabradine, used for treatment of chronic heart failure and chronic stable angina.